Question 1

Does the TRIUMPH-1 data change the verdict on retatrutide?

Accepted Answer

Significantly. Phase 2 showing 24% weight loss was interesting. Phase 3 confirming 28.3% at 72 weeks (completers) and 30.3% at 80 weeks in the heavier cohort is a different tier of result , that's sleeve gastrectomy territory. The drug is real, the mechanism works, and Lilly has the manufacturing to deliver it at scale. What changes next is: full peer-reviewed Phase 3 publication, FDA submission, and approval , none of which has happened as of September 2026.

Question 2

Should I wait for retatrutide instead of starting tirzepatide?

Accepted Answer

Only if waiting is cost-free for you. Obesity has compounding metabolic consequences , every year untreated adds cardiovascular risk, joint load, insulin resistance progression. Tirzepatide produces 22%+ weight loss in Phase 3, which is genuinely exceptional by any prior standard. If you qualify and can access it, starting tirzepatide now and considering retatrutide after approval is rational. Waiting 1–2 years in an untreated state to chase the slightly higher number is a real cost.

Question 3

What does the glucagon receptor actually add?

Accepted Answer

Two things that GLP-1 and GIP don't deliver as directly: increased resting energy expenditure (your body burns more at rest) and direct hepatic fat oxidation (the liver actively burns fat rather than just stopping new fat synthesis). That's why retatrutide's liver fat reduction data is interesting for MASLD/NASH , it's a mechanistically different intervention than just appetite suppression. The cost of adding glucagon is a mild resting heart rate increase at high doses, which appears manageable but needs longer follow-up.

Question 4

Is retatrutide available outside clinical trials?

Accepted Answer

Officially: no. Grey-market peptide suppliers sell research-grade retatrutide but with no regulatory oversight, verified purity, or guaranteed dosing accuracy. This is categorically different from using an approved drug. The risk calculus changes when you're self-injecting an unverified compound at weight-loss doses. We're not going to pretend that risk doesn't exist.

Question 5

What's the difference between the 24.2% Phase 2 result and the 28.3% Phase 3 result?

Accepted Answer

Phase 2 ran 48 weeks with a smaller sample (n=338). Phase 3 TRIUMPH-1 ran 72–80 weeks with ~2,339 participants. The longer duration explains much of the gap , these drugs continue producing weight loss past week 48 as people continue titrating and the metabolic adaptation deepens. The Phase 3 number is the more reliable signal for what people would actually experience on a full treatment course.

Question 6

Will I lose muscle on retatrutide?

Accepted Answer

Almost certainly some , that's true of any significant weight loss. Retatrutide's Phase 2 paper didn't publish detailed lean mass composition data at the level SURMOUNT did for tirzepatide. Given the larger total weight loss, the absolute lean mass lost could be higher even if the percentage is similar. The answer for both drugs is the same: protein intake above 1.2g/kg bodyweight and progressive resistance training are the proven tools to shift the ratio. Neither drug preserves muscle on its own.

Question 7

If both drugs are from Eli Lilly, will retatrutide replace tirzepatide?

Accepted Answer

Probably not replace , stratify. Lilly has a pattern of running drugs in parallel market segments. Tirzepatide will likely remain the entry drug , widely prescribed, well-understood, and eventually off-patent. Retatrutide, if approved, would be positioned as the high-efficacy option for people who need 25%+ weight loss or who haven't hit target on tirzepatide. Think of it like Lilly's insulin tiers , they coexist at different price and efficacy points.

Question 8

What about the heart rate increase with retatrutide?

Accepted Answer

Phase 2 data showed 5–7 bpm resting heart rate increase at higher doses, driven by glucagon receptor activation. Palpitations were reported in 2–11% of trial participants vs ~2% placebo , none classified as serious cardiac events. For most people this is a manageable side effect. For people with baseline tachycardia, arrhythmia history, or significant cardiovascular disease, it's a conversation to have explicitly with a physician before starting. The long-term cardiac implications won't be fully characterized until TRIUMPH-Outcomes reports in 2029.

Question 9

What happens when I stop either of these?

Accepted Answer

Weight comes back. SURMOUNT-4 measured it precisely: tirzepatide patients who switched to placebo regained 14% of body weight in the follow-up period, vs continued weight loss in the treatment arm. The mechanism stops when the drug stops. That's not a flaw , it's how receptor agonism works. Plan for these as long-term medications, not a course you finish.

	Tirzepatide	Retatrutide
Category	Dual GLP-1/GIP receptor agonist	Triple GLP-1/GIP/glucagon receptor agonist
Mechanism	Activates GLP-1 (appetite suppression, gastric emptying) and GIP (insulin sensitivity, adipose fat signaling). The GIP component also appears to blunt GLP-1-driven nausea.	Adds glucagon receptor activation on top of GLP-1 + GIP. Glucagon directly drives hepatic fat oxidation, increases resting energy expenditure, and promotes fat mobilization from adipose tissue , the third lever that tirz doesn't have.
Standard dose range	2.5mg → 15mg weekly (injection). Titration typically 4–8 weeks per step.	Phase 3 doses: up to 12mg weekly. Titration protocol mirrors tirz structure. No approved dose exists yet.
Injection frequency	Once weekly (subcutaneous injection)	Once weekly (subcutaneous injection)
Weight loss , Phase 3 result	22.5% at 72 weeks, 15mg (SURMOUNT-1). 63% of participants lost ≥20% body weight.	28.3% at 72 weeks, 12mg (TRIUMPH-1, completers). 30.3% at 80 weeks in BMI ≥35 cohort. Phase 3 peer-reviewed data pending.
Percentage achieving ≥25% weight loss	~39.7% of patients at 15mg reached ≥25% loss (SURMOUNT-1 secondary endpoint)	Majority of TRIUMPH-1 completers exceeded 25% , exact figure pending full publication. Phase 2 showed 39% at 12mg.
Top side effects	Nausea (~31%), diarrhea (~23%), constipation (~18%), vomiting (~12%). GI events peak at dose transitions, typically resolve within 2–3 weeks.	Similar GI profile to tirz. Additional: dose-dependent resting heart rate increase of 5–7 bpm at higher doses (glucagon receptor effect). Palpitations reported in 2–11% vs ~2% placebo in trials.
Evidence tier	Tier 1 , Phase 3 complete and peer-reviewed, FDA-approved for T2D and obesity, SURPASS-CVOT cardiovascular data published	Tier 2 , Phase 3 TRIUMPH-1 topline positive (May 2026), TRIUMPH-2 positive (July 2026), full peer-reviewed publication and FDA submission pending
FDA approval	Mounjaro (T2D, 2022), Zepbound (obesity, 2023). Both injectable. No oral form.	Not approved. Phase 3 data readouts ongoing through 2026. FDA submission expected post-Phase 3 completion. Earliest approval estimate: 2027–2028.
Compounding / research access	Compounding essentially ended following FDA shortage resolution in 2025. Some 503A pharmacies operate in a narrower exception. Branded supply is the practical route.	Research-grade peptide only. No compounding ecosystem because there is no approved drug to compound. Available through grey-market peptide suppliers at unverified quality and legality.
Approximate monthly cost (2026)	$299/mo via LillyDirect self-pay program (lower doses). ~$499–1,086 branded list price. Insurance copay as low as $25 for covered plans.	No commercial pricing. Research-grade sources vary; not insurable and quality unverified.
Additional benefits in trials	Improvement in A1C, triglycerides, blood pressure. SURMOUNT-CVOT ongoing for obesity-specific CV data.	TRIUMPH-4: 75.8% reduction in knee osteoarthritis pain. ~20% LDL reduction. 72% reversal of prediabetes to normoglycemia. Sleep apnea improvement (~61% reduction in breathing pauses). These secondary findings suggest a broader metabolic profile than any approved GLP-1 agent.

Tirzepatide vs Retatrutide